Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

被引：2295

作者：

Ryan, Charles J. ^{[1
]}

Smith, Matthew R. ^{[2
]}

de Bono, Johann S. ^{[4
,5
]}

Molina, Arturo ^{[6
]}

Logothetis, Christopher J. ^{[8
]}

de Souza, Paul ^{[9
]}

Fizazi, Karim ^{[12
]}

Mainwaring, Paul ^{[10
]}

Piulats, Josep M. ^{[13
]}

Ng, Siobhan ^{[11
]}

Carles, Joan ^{[14
]}

Mulders, Peter F. A. ^{[15
]}

Basch, Ethan ^{[17
]}

Small, Eric J. ^{[1
]}

Saad, Fred ^{[18
]}

Schrijvers, Dirk ^{[21
]}

Van Poppel, Hendrik ^{[22
]}

Mukherjee, Som D. ^{[19
]}

Suttmann, Henrik ^{[23
]}

Gerritsen, Winald R. ^{[16
]}

Flaig, Thomas W. ^{[24
]}

George, Daniel J. ^{[25
]}

Yu, Evan Y. ^{[26
]}

Efstathiou, Eleni ^{[8
,27
]}

Pantuck, Allan ^{[7
]}

Winquist, Eric ^{[20
]}

Higano, Celestia S. ^{[26
]}

Taplin, Mary-Ellen ^{[3
]}

Park, Youn ^{[6
]}

Kheoh, Thian ^{[6
]}

Griffin, Thomas ^{[6
]}

Scher, Howard I. ^{[17
]}

Rathkopf, Dana E. ^{[17
]}

机构：

[1] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA

[2] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[3] Dana Farber Canc Inst, Boston, MA 02115 USA

[4] Inst Canc Res, Sutton, Surrey, England

[5] Royal Marsden Hosp, Sutton, Surrey, England

[6] Janssen Res & Dev, Los Angeles, CA USA

[7] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[8] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[9] St George Private Hosp, Kogarah, NSW, Australia

[10] Haematol & Oncol Clin Australia, Brisbane, Qld, Australia

[11] St John God Hosp, Subiaco, WA, Australia

[12] Univ Paris 11, Inst Gustave Roussy, Villejuif, France

[13] Inst Catala Oncol Hosp, Barcelona, Spain

[14] Univ Vall dHebron, Barcelona, Spain

[15] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands

[16] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands

[17] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[18] Univ Montreal, Montreal, PQ, Canada

[19] Juravinski Canc Ctr, Hamilton Hlth Serv, Hamilton, ON, Canada

[20] London Hlth Sci Ctr, London, ON, Canada

[21] Hosp Network Antwerp ZNA Middelheim, Antwerp, Belgium

[22] Katholieke Univ Leuven Hosp, Louvain, Belgium

[23] Urologikum Hamburg, Hamburg, Germany

[24] Univ Colorado, Ctr Canc, Aurora, CO USA

[25] Duke Univ Hosp, Med Ctr, Durham, NC USA

[26] Univ Washington, Seattle, WA 98195 USA

[27] Univ Athens, Sch Med, Alexandra Hosp, Dept Clin Therapeut, GR-10679 Athens, Greece

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2013年 / 368卷 / 02期

关键词：

HUMAN CYTOCHROME P450(17-ALPHA); HORMONAL-THERAPY; CONTROLLED-TRIAL; END-POINTS; ACETATE; MITOXANTRONE; INHIBITION; PREDNISONE; DOCETAXEL; CYP17;

D O I：

10.1056/NEJMoa1209096

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BACKGROUND Abiraterone acetate, an androgen biosynthesis inhibitor, improves overall survival in patients with metastatic castration-resistant prostate cancer after chemotherapy. We evaluated this agent in patients who had not received previous chemotherapy. METHODS In this double-blind study, we randomly assigned 1088 patients to receive abiraterone acetate (1000 mg) plus prednisone (5 mg twice daily) or placebo plus prednisone. The coprimary end points were radiographic progression-free survival and overall survival. RESULTS The study was unblinded after a planned interim analysis that was performed after 43% of the expected deaths had occurred. The median radiographic progression-free survival was 16.5 months with abiraterone-prednisone and 8.3 months with prednisone alone (hazard ratio for abiraterone-prednisone vs. prednisone alone, 0.53; 95% confidence interval [CI], 0.45 to 0.62; P<0.001). Over a median follow-up period of 22.2 months, overall survival was improved with abiraterone-prednisone (median not reached, vs. 27.2 months for prednisone alone; hazard ratio, 0.75; 95% CI, 0.61 to 0.93; P = 0.01) but did not cross the efficacy boundary. Abiraterone-prednisone showed superiority over prednisone alone with respect to time to initiation of cytotoxic chemotherapy, opiate use for cancer-related pain, prostate-specific antigen progression, and decline in performance status. Grade 3 or 4 mineralocorticoid- related adverse events and abnormalities on liver-function testing were more common with abiraterone-prednisone. CONCLUSIONS Abiraterone improved radiographic progression-free survival, showed a trend toward improved overall survival, and significantly delayed clinical decline and initiation of chemotherapy in patients with metastatic castration-resistant prostate cancer. (Funded by Janssen Research and Development, formerly Cougar Biotechnology; ClinicalTrials.gov number, NCT00887198.)

引用

页码：138 / 148

页数：11

共 26 条

[1]

[Anonymous], CA CANC J CLIN, DOI DOI 10.3322/CAAC.20107

[2] Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer [J].

Attard, G ;

Belldegrun, AS ;

de Bono, JS .

BJU INTERNATIONAL, 2005, 96 (09) :1241-1246

[3] Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer [J].

Attard, Gerhardt ;

Reid, Alison H. M. ;

A'Hern, Roger ;

Parker, Christopher ;

Oommen, Nikhil Babu ;

Folkerd, Elizabeth ;

Messiou, Christina ;

Molife, L. Rhoda ;

Maier, Gal ;

Thompson, Emilda ;

Olmos, David ;

Sinha, Rajesh ;

Lee, Gloria ;

Dowsett, Mitch ;

Kaye, Stan B. ;

Dearnaley, David ;

Kheoh, Thian ;

Molina, Arturo ;

de Bono, Johann S. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (23) :3742-3748

[4] Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17 alpha) inhibitors [J].

Barrie, SE ;

Haynes, BP ;

Potter, GA ;

Chan, FCY ;

Goddard, PM ;

Dowsett, M ;

Jarman, M .

JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1997, 60 (5-6) :347-351

[5] A CONTROLLED TRIAL OF LEUPROLIDE WITH AND WITHOUT FLUTAMIDE IN PROSTATIC-CARCINOMA [J].

CRAWFORD, ED ;

EISENBERGER, MA ;

MCLEOD, DG ;

SPAULDING, JT ;

BENSON, R ;

DORR, FA ;

BLUMENSTEIN, BA ;

DAVIS, MA ;

GOODMAN, PJ .

NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (07) :419-424

[6] Abiraterone and Increased Survival in Metastatic Prostate Cancer [J].

De Bono, Johann S. ;

Logothetis, Christopher J. ;

Molina, Arturo ;

Fizazi, Karim ;

North, Scott ;

Chu, Luis ;

Chi, Kim N. ;

Jones, Robert J. ;

Goodman, Oscar B., Jr. ;

Saad, Fred ;

Staffurth, John N. ;

Mainwaring, Paul ;

Harland, Stephen ;

Flaig, Thomas W. ;

Hutson, Thomas E. ;

Cheng, Tina ;

Patterson, Helen ;

Hainsworth, John D. ;

Ryan, Charles J. ;

Sternberg, Cora N. ;

Ellard, Susan L. ;

Flechon, Aude ;

Saleh, Mansoor ;

Scholz, Mark ;

Efstathiou, Eleni ;

Zivi, Andrea ;

Bianchini, Diletta ;

Loriot, Yohann ;

Chieffo, Nicole ;

Thian Kheoh ;

Haqq, Christopher M. ;

Scher, Howard I. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (21) :1995-2005

[7] Effects of Abiraterone Acetate on Androgen Signaling in Castrate-Resistant Prostate Cancer in Bone [J].

Efstathiou, Eleni ;

Titus, Mark ;

Tsavachidou, Dimitra ;

Tzelepi, Vassiliki ;

Wen, Sijin ;

Anh Hoang ;

Molina, Arturo ;

Chieffo, Nicole ;

Smith, Lisa A. ;

Karlou, Maria ;

Troncoso, Patricia ;

Logothetis, Christopher J. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (06) :637-643

[8]

Engel-Nitz Nicole M, 2011, Cancer Manag Res, V3, P233, DOI 10.2147/CMR.S21033

[9] Castration-resistant prostate cancer: Many treatments, many options, many challenges ahead [J].

Garcia, Jorge A. ;

Rini, Brian I. .

CANCER, 2012, 118 (10) :2583-2593

[10] A Population-based Study of Prostate Cancer Chemotherapy [J].

Harris, V. ;

Lloyd, K. ;

Forsey, S. ;

Rogers, P. ;

Roche, M. ;

Parker, C. .

CLINICAL ONCOLOGY, 2011, 23 (10) :706-708

← 1 2 3 →